



March 12, 2014

Revance Therapeutics to Release Fourth Quarter and Full Year 2013 Financial Results and Host Conference Call on Wednesday, March 26, 2014

NEWARK, Calif., March 12, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company which develops botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will release fourth quarter and full year 2013 financial results on Wednesday, March 26, 2014 after the close of market. Revance will host a conference call and a live Internet webcast at 1:30pm PT/4:30pm ET on the same day to discuss the results and provide a business update.

Individuals interested in listening to the conference call may do so by dialing (855) 453-3827 for domestic callers, or (484) 756-4301 for international callers, or from the webcast link in the investor relations section of the Company's website at: www.revance.com. Participants should allow approximately five to 10 minutes prior to the call's start time to visit the site and to download any streaming media software needed to listen to the Internet webcast. The webcast will be available in the Investor Relations section on the Company's website for 30 days following the completion of the call.

About Revance Therapeutics, Inc.

Revance is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The Company is leveraging its proprietary portfolio of botulinum toxin compounds combined with its patented TransMTS® peptide delivery system to address unmet needs in the large and growing aesthetic and therapeutic botulinum toxin market. Revance's proprietary TranMTS technology enables transcutaneous delivery of botulinum toxin A, eliminating the need for injections. The Company's lead product candidate, RT001, is a topical formulation of botulinum toxin type A, which has the potential to be the first commercially-available non-injectable dose form. RT001 is being evaluated in a broad clinical program that includes aesthetic indications such as crow's feet lines (wrinkles around the eyes) and therapeutic indications such as hyperhidrosis (excessive sweating) and migraine headache. Revance also has a second product candidate, RT002, a novel injectable formulation of botulinum toxin type A designed to be more targeted and longer lasting than currently available botulinum toxin injectable products.

CONTACT: Westwicke Partners

Ana Petrovic

(415) 513-1281

ana.petrovic@westwicke.com